Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1590238 | 0.99 | HTR6 (0.62) | HTR6PIK3CDHDAC3HDAC4HDAC1 | |
| SCHEMBL1590499 | 0.92 | HTR6 (0.63) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL1590414 | 0.91 | HTR6 (0.62) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12702571 | 0.85 | HTR6 (0.62) | HTR6ADRA2AHTR2CMLNR | |
| Hydrochloric Acid SCHEMBL1590421 | 0.84 | HTR6 (0.61) | HTR6ADRA2AHTR2CMLNR | |
| SCHEMBL1590451 | 0.83 | HTR6 (0.67) | HTR6HTR2CPKM | |
| SCHEMBL1590132 | 0.83 | HTR6 (0.67) | HTR6HTR2CMLNRPKM | |
| SCHEMBL1590191 | 0.79 | HTR6 (0.60) | HTR6ADRA2AHTR2C | |
| SCHEMBL12702633 | 0.79 | HTR6 (0.73) | HTR6 | |
| SCHEMBL1590216 | 0.79 | HTR6 (0.67) | HTR6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | claimed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| EP-2116546-A1 | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | HTR6, HTR2A, HTR4 | HTR6 1/4885PIK3CD 3016/4885HDAC3 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.